Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kaisa Mustonen"'
Autor:
Azam Rashidian, Enni-Kaisa Mustonen, Thales Kronenberger, Matthias Schwab, Oliver Burk, Stefan A. Laufer, Tatu Pantsar
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 20, Iss , Pp 3004-3018 (2022)
Pregnane X receptor (PXR) is a nuclear receptor with an essential role in regulating drug metabolism genes. While the mechanism of action for ligand-mediated PXR agonism is well-examined, its ligand-mediated inhibition or antagonism is poorly underst
Externí odkaz:
https://doaj.org/article/390d4c67451d49668c763e41795e9da7
Autor:
Enni-Kaisa Mustonen, Tatu Pantsar, Azam Rashidian, Juliander Reiner, Matthias Schwab, Stefan Laufer, Oliver Burk
Publikováno v:
Cells, Vol 11, Iss 8, p 1299 (2022)
Small-molecule protein kinase inhibitors are used for the treatment of cancer, but off-target effects hinder their clinical use. Especially off-target activation of the pregnane X receptor (PXR) has to be considered, as it not only governs drug metab
Externí odkaz:
https://doaj.org/article/03922f629772424eb174ca323172c458
Autor:
Anna Autio, Danny Croghan, Kaisa Mustonen, Timo Penttilä, Jeffrey M. Welker, Kashif Noor, Anssi Rauhala, Mika Aurela, Bjørn Kløve, Eric S. Klein, Hannah Bailey, Leo-Juhani Meriö, Jussi Vuorenmaa, Timo Kumpula, Anton Kuzmin, Filip Muhic, Pasi Korpelainen, Pertti Ala-aho, Annalea Lohila, Hannu Marttila, Valtteri Hyöky
Subarctic ecohydrological processes are changing rapidly, but detailed and integrated ecohydrological investigations are not as widespread as necessary. We introduce an integrated research catchment site (Pallas) for atmosphere, ecosystems, and ecohy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecb3cb41997ceaefe1db7e148bce3b5f
http://hdl.handle.net/10138/334814
http://hdl.handle.net/10138/334814
Publikováno v:
Regulatory Toxicology and Pharmacology. 90:328-341
Antisense oligonucleotides, short interfering RNAs (siRNAs) and aptamers are oligonucleotide-based pharmaceuticals with a promising role in targeted therapies. Currently, five oligonucleotide-based pharmaceuticals have achieved marketing authorizatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36f083a230d72250b472dd4d362bb461
https://doi.org/10.1016/j.yrtph.2017.09.028
https://doi.org/10.1016/j.yrtph.2017.09.028
Autor:
Oliver Burk, Hanno Nieß, Enni-Kaisa Mustonen, Tatu Pantsar, Matthias Schwab, Serene M. L. Lee
Publikováno v:
Archives of Biochemistry and Biophysics
Farnesoid X receptor (FXR, NR1H4) is a ligand-activated nuclear receptor, which regulates bile acid, lipid and glucose metabolism. Due to these functions, FXR has been investigated as a potential drug target for the treatment of liver diseases, such
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f34fe24cb2f482d31584f50b70fb6e6d